ATARA Biotherapeutics (ATRA) Misses Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
March 1, 2021 4:05 PM ESTOn track to complete the rolling tab-cel® BLA submission in Q3 2021 for patients with EBV+ PTLD through active and productive discussions with FDA
On track with ATA188 Phase 2 RCT (randomized controlled trial) enrollment in patients with progressive forms of MS, enabling an interim analysis in H1 2022
Continued progress on advancing CAR T portfolio, enabling clinical data presentation for mesothelin-targeted ATA2271 in Q4 2021 and IND submission for novel allogeneic CD19 CAR T ATA3219 in Q4 2021/Q1 2022
Conference Call and Webcast Today at 4:30... More
